Intellia Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 526
- Market Cap
- $2.3B
- Website
- http://www.intelliatx.com
- Introduction
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.
Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In
Intellia Therapeutics reports positive Phase 2 data for NTLA-2002, showing deep attack rate reductions and potential for a functional cure for hereditary angioedema (HAE). Eight of 11 patients in the 50 mg arm were completely attack-free post-infusion. Data published in The New England Journal of Medicine and to be presented at the 2024 ACAAI Scientific Meeting. Intellia is actively screening patients for the global pivotal Phase 3 HAELO study.
Related Clinical Trials:
Intellia reports promising Phase 2 results for HAE treatment
Intellia Therapeutics announces positive Phase 2 data for NTLA-2002, a gene editing therapy for hereditary angioedema (HAE), showing significant attack rate reductions and potential for a functional cure. The company selects the 50 mg dose for further evaluation in the Phase 3 HAELO study and aims to redefine HAE treatment. Intellia also reports progress in other clinical programs and a strong financial position.
Hemoglobinopathy Treatment Advancements: Global Market Forecast 2024
The hemoglobinopathies treatment market is projected to grow from $8.2 billion in 2023 to $13.2 billion by 2028, driven by genetic inheritance, advancements in cell-based gene therapies, and personalized medicine. Key players include Pfizer, Sanofi, and Vertex Pharmaceuticals.
Promising Outlook with NTLA-2002's Impressive Phase II Results and ...
BMO Capital's Kostas Biliouris maintains Buy rating on Intellia Therapeutics (NTLA) with $70.00 target, citing NTLA-2002's Phase II success, expected Oct 24th data release, and long-term HAE attack elimination potential.
Intellia launches Phase 3 trial of gene-editing therapy NTLA-2002
Intellia Therapeutics initiated a Phase 3 trial, HAELO, to assess NTLA-2002, a single-dose gene-editing therapy for hereditary angioedema (HAE). The trial follows promising Phase 1/2 data showing a 98% reduction in swelling attacks. HAELO will evaluate NTLA-2002 in 60 HAE patients, aiming to confirm its efficacy in preventing attacks over six months.
The Latest Updates From the Gene-Editing Clinical Trials (October 2024)
Intellia Therapeutics initiates Phase 3 trial of NTLA-2002 for hereditary angioedema; Poseida Therapeutics reports positive Phase 1 data for P-BCMA-ALLO1 in multiple myeloma; YolTech Therapeutics receives FDA orphan drug designation for YOLT-203 to treat primary hyperoxaluria type 1; KSQ Therapeutics gets FDA clearance for Phase 1/2 trial of CRISPR-edited TIL therapy KSQ-004EX.
Related Clinical Trials:
Intellia Therapeutics begins Phase III trial of hereditary angioedema gene therapy
Intellia Therapeutics initiates Phase III HAELO trial of NTLA-2002, an in-vivo gene editing therapy for hereditary angioedema, with a placebo-controlled study assessing efficacy and safety in 60 adult subjects.
Intellia starts late-stage test of CRISPR therapy for rare swelling disease
Intellia Therapeutics initiates Phase 3 HAELO trial for NTLA-2002, a CRISPR gene editing treatment targeting hereditary angioedema, aiming to reduce attacks and kallikrein protein levels. The trial will involve 60 adults, with a 2-to-1 randomization to NTLA-2002 or placebo, followed by a crossover phase. Intellia seeks to compete with Pfizer, BridgeBio Pharma, and Alnylam in rare disease treatments.
Intellia Therapeutics Announces Initiation of HAELO Phase 3 Study of NTLA-2002
Intellia Therapeutics initiates HAELO Phase 3 study of NTLA-2002, an in vivo CRISPR gene editing treatment for hereditary angioedema (HAE), designed as a single-dose to prevent life-threatening swelling attacks. The study will evaluate efficacy and safety in 60 adults with Type I or II HAE, randomized 2:1 to receive a 50 mg infusion of NTLA-2002 or placebo, with primary endpoint being the change in HAE attacks from week 5 to 28.
Related Clinical Trials:
© Copyright 2025. All Rights Reserved by MedPath